About Gene Therapy
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy, which replaces faulty genes with normal ones in the body, is particularly promising and currently gaining attention. It has potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.
Covered in this report
The report covers the present scenario and the growth prospects of the gene therapy for ovarian cancer for 2018-2022. To calculate the market size, the report considers the revenue generated from the gene therapy.
Technavio's report, Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
• Takara Bio
• Lokon Pharma
• SiBiono GeneTech
• The adoption of replacement gene therapy
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: GENE THERAPY FOR OVARIAN CANCER: AN INSIGHT
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
• Mid-stage molecules (Phase II and I/II), 2017
• Early-stage molecules (Phase I), 2017
• Inactive molecules, 2017
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 10: THERAPEUTIC ASSESSMENT (BY TARGET)
PART 11: KEY COMPANIES
• Active companies: Category and parameters
• List of abbreviations
List of Exhibits
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline molecules by vendors
Exhibit 04: Pipeline molecules by numbers
Exhibit 05: Pipeline molecules by percentage
Exhibit 06: Overview: p53 gene therapy
Exhibit 07: Clinical trials description of p53 gene
Exhibit 08: Overview: Ofranergene obadenovec
Exhibit 09: Clinical trials description of Ofranergene obadenovec
Exhibit 10: Overview: GEN-1
Exhibit 11: Clinical trials description of GEN-1
Exhibit 12: Overview: LOAd703
Exhibit 13: Clinical trials description of LOAd703
Exhibit 14: Overview: ONCOS-102
Exhibit 15: Clinical trials description of ONCOS-102
Exhibit 16: Overview: Aglatimagene besadenovec
Exhibit 17: Clinical trials description of Aglatimagene besadenovec
Exhibit 18: Overview: TBI-1301
Exhibit 19: Clinical trials description of TBI-1301
Exhibit 20: Overview: BC-819
Exhibit 21: Clinical trials description of BC-819
Exhibit 22: Overview: MetXia
Exhibit 23: Overview: Gene therapy for ovarian cancer
Exhibit 24: Analysis by type of ovarian cancer
Exhibit 25: Overview of indication
Exhibit 26: Assessment by RoA
Exhibit 27: Segmentation of pipeline by stage and RoA
Exhibit 28: Assessment by target
Exhibit 29: Vendor landscape
Exhibit 30: Segmentation of companies
Exhibit 31: Overview: Advantagene, 2017
Exhibit 32: Overview: CELSION, 2017
Exhibit 33: Overview: Lokon Pharma, 2017
Exhibit 34: Overview: SiBiono GeneTech, 2017
Exhibit 35: Overview: Takara Bio, 2017
Exhibit 36: Overview: Targovax, 2017
Exhibit 37: Overview: Vascular Biogencies, 2017